stoxline Quote Chart Rank Option Currency Glossary
Calidi Biotherapeutics, Inc. (CLDI)
0.225  -0.045 (-16.67%)    06-12 16:00
Open: 0.2438
High: 0.2438
Volume: 1,974,006
Pre. Close: 0.27
Low: 0.2169
Market Cap: 14(M)
Technical analysis
2024-06-12 4:21:08 PM
Short term     
Mid term     
Targets 6-month :  0.43 1-year :  0.57
Resists First :  0.37 Second :  0.49
Pivot price 0.22
Supports First :  0.18 Second :  0.15
MAs MA(5) :  0.21 MA(20) :  0.23
MA(100) :  0.48 MA(250) :  3.46
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  16.3 D(3) :  11.6
RSI RSI(14): 46.9
52-week High :  13.78 Low :  0.14
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CLDI ] has closed above bottom band by 43.3%. Bollinger Bands are 71.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.24 - 0.25 0.25 - 0.25
Low: 0.21 - 0.22 0.22 - 0.22
Close: 0.22 - 0.22 0.22 - 0.22
Company Description

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.

Headline News

Tue, 11 Jun 2024
Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13 - Business Wire

Mon, 10 Jun 2024
Why Calidi Biotherapeutics is Moving Higher Monday - Calidi Biotherapeutics (AMEX:CLDI) - Benzinga

Mon, 10 Jun 2024
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi's Revolutionary RTNova Virotherapy for ... - Business Wire

Sat, 01 Jun 2024
Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Stock Price Down 35% - Defense World

Sat, 01 Jun 2024
Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Stock Price Down 35% - Defense World

Fri, 31 May 2024
Why Calidi Biotherapeutics (CLDI) Stock Is Getting Hammered - Calidi Biotherapeutics (AMEX:CLDI) - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 35 (M)
Shares Float 21 (M)
Held by Insiders 47.4 (%)
Held by Institutions 5 (%)
Shares Short 11 (K)
Shares Short P.Month 14 (K)
Stock Financials
EPS -0.59
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.03
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -173 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.78
Qtrly Earnings Growth 0 %
Operating Cash Flow -26 (M)
Levered Free Cash Flow -39 (M)
Stock Valuations
PE Ratio -0.38
PEG Ratio 0
Price to Book value -7.32
Price to Sales 0
Price to Cash Flow -0.31
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android